NEW YORK (GenomeWeb News) – Sequenom reported after the close of the market Thursday that its third-quarter revenues jumped 92 percent from the third quarter of 2012, driven by sales of its MaterniT21 Plus test.

The San Diego-based firm brought in total revenues of $44 million for the three months ended Sept. 30, up from $22.9 million for the third quarter of 2012 and up from $34.9 million in the second quarter of 2013. It beat the consensus Wall Street estimate of $40.6 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.